EVAX vs FDMT

Evaxion A/S vs 4D Molecular Therapeutics, Inc. — Valuation Comparison 2026

EVAX

Biological Products, (No Diagnostic Substances)
Evaxion A/S
Quality
1.9
out of 10
Value Trap
12
SAFE
Price
$4.00
Last close
Models
7/13
Active
VS

FDMT

Biological Products, (No Diagnostic Substances)
4D Molecular Therapeutics, Inc.
Quality
7.1
out of 10
Value Trap
24
SAFE
Price
$9.91
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType EVAX Fair ValueEVAX Upside FDMT Fair ValueFDMT Upside
Bayesian DCF Intrinsic $1.07 -73.1% $2.84 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.18 -95.5% $4.34 -50.0%
Dynamic NAV Asset-Based $1.02 -74.5% $8.24 -16.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EVAX vs FDMT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EVAX vs FDMT — Which Stock Is More Undervalued?

FDMT scores higher with a 7.1/10 quality rating vs EVAX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evaxion A/S (EVAX) and 4D Molecular Therapeutics, Inc. (FDMT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EVAX currently trades at $4.00 with a QOC of 1.9/10, while FDMT trades at $9.91 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).